Diferencia entre revisiones de «Template:Toxoplasmosis Antibiotics»

(Convert to AntibioticDose with disease=Toxoplasmosis for SMW linking)
Línea 1: Línea 1:
====Immunocompetent====
====Immunocompetent====
''Antibiotics only needed if patient has severe symptoms''
''Antibiotics only needed if patient has severe symptoms''
*[[Pyrimethamine]] 200mg PO one dose (for loading) THEN 50mg PO q24hrs x4wks AND
*{{AntibioticDose|disease=Toxoplasmosis|drug=Pyrimethamine|dose=200mg PO load then 50mg PO q24hrs x 4 weeks|context=Immunocompetent with Leucovorin and Sulfadiazine|population=Adult}} AND
**[[Leucovorin]] 10mg PO q24hrs AND
**{{AntibioticDose|disease=Toxoplasmosis|drug=Leucovorin|dose=10mg PO q24hrs|context=Immunocompetent adjunct|population=Adult}} AND
**[[Sulfadiazine]] 1g PO q6hrs
**{{AntibioticDose|disease=Toxoplasmosis|drug=Sulfadiazine|dose=1g PO q6hrs|context=Immunocompetent with Pyrimethamine|population=Adult}}


====Immunosprepressed====
====Immunosprepressed====
*[[Pyrimethamine]] 200mg PO one dose (for loading) THEN 75mg PO q24hrs x4-8wks AND [[Leucovorin]] 25mg PO q24hrs PLUS
*{{AntibioticDose|disease=Toxoplasmosis|drug=Pyrimethamine|dose=200mg PO load then 75mg PO q24hrs x 4-8 weeks|context=Immunosuppressed|population=Adult}} AND {{AntibioticDose|disease=Toxoplasmosis|drug=Leucovorin|dose=25mg PO q24hrs|context=Immunosuppressed adjunct|population=Adult}} PLUS
**[[Sulfadiazine]] 1500mg PO q6hrs OR
**{{AntibioticDose|disease=Toxoplasmosis|drug=Sulfadiazine|dose=1500mg PO q6hrs|context=Immunosuppressed with Pyrimethamine|population=Adult}} OR
**[[Clindamycin]] 600mg PO or IV q6hrs OR
**{{AntibioticDose|disease=Toxoplasmosis|drug=Clindamycin|dose=600mg PO or IV q6hrs|context=Immunosuppressed alt|population=Adult}} OR
**[[Azithromycin]] 12000mg PO q24hrs OR
**{{AntibioticDose|disease=Toxoplasmosis|drug=Azithromycin|dose=1200mg PO q24hrs|context=Immunosuppressed alt|population=Adult}} OR
**[[Atovaquone]] 1500mg PO q12hrs
**[[Atovaquone]] 1500mg PO q12hrs
OR
OR
*[[TMP/SMX]] 5mg/kg IV q12hrs
*{{AntibioticDose|disease=Toxoplasmosis|drug=Trimethoprim-Sulfamethoxazole DS|dose=5mg/kg IV q12hrs|context=Immunosuppressed alt|display=TMP/SMX|population=Adult}}


====Pregnant====
====Pregnant====
*[[Spiramycin]] 1 g orally every 8 hours<ref>Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. Jan 2013;35(1):78-9.</ref>
*{{AntibioticDose|disease=Toxoplasmosis|drug=Spiramycin|dose=1g PO q8hrs|context=Pregnant|population=Adult}}<ref>Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. Jan 2013;35(1):78-9.</ref>
**If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses)
**If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses)
**Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR
**Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR
*[[Pyrimethamine]] (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND
*[[Pyrimethamine]] (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND
**[[Leucovorin]] 10-25 mg/day orally to prevent bone marrow suppression
**[[Leucovorin]] 10-25 mg/day orally to prevent bone marrow suppression

Revisión del 01:31 20 mar 2026

Immunocompetent

Antibiotics only needed if patient has severe symptoms

Immunosprepressed

OR

Pregnant

  • Spiramycin 1g PO q8hrs[1]
    • If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses)
    • Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR
  • Pyrimethamine (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND
    • Leucovorin 10-25 mg/day orally to prevent bone marrow suppression
  1. Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. Jan 2013;35(1):78-9.